[{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Luis A. Diaz<\/i><\/u><\/presenter>. Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"c9d2b8e0-235b-4c73-bde7-e84fef7655fe","ControlNumber":"10101","DisclosureBlock":"&nbsp;<b>L.A. Diaz:<\/b> None.","End":"4\/18\/2023 2:31:00 PM","HasWebcast":null,"Highlights":[],"Id":"8421","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"1","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Luis Diaz, MD","PresenterKey":"37142ae0-b095-443b-980a-1a6ca2e14d1f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Chairperson","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 2:30:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Chairperson","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Muhammed Murtaza<\/i><\/u><\/presenter>. University of Wisconsin Carbone Cancer Center, Madison, WI","CSlideId":"","ControlKey":"e4c40007-6fd3-4b39-84d6-8380cea23f50","ControlNumber":"10531","DisclosureBlock":"&nbsp;<b>&nbsp;M. Murtaza:<\/b>  ; Castle Biosciences, Inc. ; Castle Biosciences, Inc. ; Castle Biosciences, Inc. ; Castle Biosciences, Inc. ; Castle Biosciences, Inc. ; Exact Sciences. ; Exact Sciences. ; Exact Sciences. ; Exact Sciences. ; Exact Sciences. ; PetDx. ; PetDx. ; PetDx. ; PetDx. ; PetDx. ; Translational Genomics Research Institute. ; Translational Genomics Research Institute. ; Translational Genomics Research Institute. ; Translational Genomics Research Institute. ; Translational Genomics Research Institute.","End":"4\/18\/2023 2:32:00 PM","HasWebcast":null,"Highlights":[],"Id":"9570","IsPresentation":"False","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"2","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Muhammed Murtaza, MBBS;PhD","PresenterKey":"dc26c9ab-5fe1-43a5-aaee-97990968c93d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Chairperson","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 2:31:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Chairperson","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Luis A. Diaz<\/i><\/u><\/presenter>. Memorial Sloan Kettering Cancer Center, New York, NY","CSlideId":"","ControlKey":"fb212fcc-9b5e-4a3d-937a-9027ba236861","ControlNumber":"11057","DisclosureBlock":"&nbsp;<b>L. A. Diaz, <\/b> None.","End":"4\/18\/2023 2:37:00 PM","HasWebcast":null,"Highlights":[],"Id":"10835","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"3","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Luis Diaz, MD","PresenterKey":"37142ae0-b095-443b-980a-1a6ca2e14d1f","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Introduction","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 2:32:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Introduction","Topics":null,"cSlideId":""},{"Abstract":"In many areas of oncology, we lack sensitive tumor-burden monitoring to guide critical decision making. While circulating tumor DNA (ctDNA) promises to enable disease monitoring, this approach is limited by the sparsity of ctDNA in the plasma. To overcome this challenge, error-corrected deep targeted sequencing has been proposed.<br \/>Nonetheless, this framework is limited by the low number of genomic equivalents (GEs, ~10<sup>3 <\/sup>\/mL of plasma), imposing a ceiling on effective sequencing depth. We have previously shown that genome-wide mutational integration through plasma whole genome sequencing (WGS) can sever the dependency between available GEs and assay sensitivity (Zviran <i>et al<\/i>, 2020). In this approach, tumor-informed mutational profiles are applied to plasma WGS, allowing detection of tumor fractions as low as 10<sup>-5<\/sup>. However, the higher cost of WGS limits practical depth of coverage (20-30X) and may limit broad adoption. Lower costs may thus allow for enhanced ctDNA cancer monitoring via WGS. We therefore applied emerging lower-cost WGS (1USD\/Gb, Almogy <i>et al<\/i>, 2022) to plasma from 7 patients with metastatic cancer at ~115x coverage depth. Read depth profiling and error rates were comparable between matched Ultima and standard platform datasets. Integration of deep learning architectures for signal to noise enrichment (Widman<i> et al<\/i>, biorxiv, 2022) with deeper WGS coverage enabled ctDNA detection at the parts per million range.<br \/>We reasoned that lower sequencing cost can be harnessed for duplex error-corrected WGS. Proof-of-concept experiments in mouse PDX samples showed ~1,500x decrease in errors. Applied to the plasma of stage IV melanoma patients (n=5), we obtained error rates ~10<sup>-7<\/sup>. We used this approach to tackle the challenging context of cancer monitoring in early-stage melanoma without matched tumor sequencing. While in uncorrected WGS, <i>de novo<\/i> mutation calling yielded limited ability to detect melanoma specific mutations, duplex-corrected WGS allowed us to harness melanoma mutational signatures for disease monitoring without matched tumor profiling. Analytic validation of our assay showed sensitive and specific cancer detection when the concentration of ctDNA was at 10<sup>-4<\/sup> concentrations. Applied to a cohort of stage III melanoma patients with negative ctDNA detection using previously described methods, we detected ctDNA in all cases (n=4), demonstrating enhanced sensitivity using duplex WGS. These data demonstrate the exciting potential of low cost WGS for ultra-sensitive ctDNA cancer monitoring. In the tumor-informed setting, deeper sequencing increased sensitivity for mutational profile detection. Moreover, the application of duplex error-correction at genome scale allowed for sensitive cancer monitoring without matched tumor profiles. We envision that the era of low-cost sequencing will empower ultra-sensitive cancer monitoring via WGS, with transformative impact on cancer care.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies: Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Liquid biopsies,Sequencing,Mutation detection,Early detection,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Alexandre  P.  Cheng<\/b><sup>1<\/sup>, Adam  J.  Widman<sup>2<\/sup>, Anushri Arora<sup>3<\/sup>, Itai Rusinek<sup>4<\/sup>, William  F.  Hooper<sup>1<\/sup>, Rebecca Murray<sup>1<\/sup>, Daniel Halmos<sup>1<\/sup>, Theophile Langanay<sup>1<\/sup>, Giorgio Inghirami<sup>1<\/sup>, Soren Germer<sup>3<\/sup>, Melissa Marton<sup>3<\/sup>, Adrienne Helland<sup>3<\/sup>, Rob Furatero<sup>3<\/sup>, Jaime McClintock<sup>3<\/sup>, Lara Winterkorn<sup>3<\/sup>, Zoe Steinsnyder<sup>3<\/sup>, Yohyoh Wang<sup>1<\/sup>, Srinivas Rajagopalan<sup>1<\/sup>, Asrar  I.  Alimohamed<sup>5<\/sup>, Murtaza  S.  Malbari<sup>1<\/sup>, Ashish Saxena<sup>1<\/sup>, Margaret  K.  Callahan<sup>2<\/sup>, Dennie  T.  Frederick<sup>6<\/sup>, Lavinia Spain<sup>7<\/sup>, Ariel Jaimovich<sup>4<\/sup>, Doron Lipson<sup>4<\/sup>, Samra Turajlic<sup>7<\/sup>, Michael  C.  Zody<sup>3<\/sup>, Nasser  K.  Altorki<sup>1<\/sup>, Jedd  D.  Wolchok<sup>1<\/sup>, Michael  A.  Postow<sup>2<\/sup>, Nicolas Robine<sup>3<\/sup>, Genevieve Boland<sup>6<\/sup>, Dan  A.  Landau<sup>1<\/sup><br><br\/><sup>1<\/sup>Weill Cornell Medical College, New York, NY,<sup>2<\/sup>Memorial Sloan Kettering Cancer Center, New York, NY,<sup>3<\/sup>New York Genome Center, New York, NY,<sup>4<\/sup>Ultima Genomics, Newark, CA,<sup>5<\/sup>Dana Farber Cancer Institute, Boston, MA,<sup>6<\/sup>Massachusetts General Hospital, Boston, MA,<sup>7<\/sup>The Francis Crick Institute, London, United Kingdom","CSlideId":"","ControlKey":"62bf0011-78e0-41ee-8b38-0c264b105ca7","ControlNumber":"3971","DisclosureBlock":"<b>&nbsp;A. P. Cheng, <\/b> <br><b>Eurofins-Viracor<\/b> Independent Contractor, Patent.<br><b>A. J. Widman, <\/b> None..<br><b>A. Arora, <\/b> None.&nbsp;<br><b>I. Rusinek, <\/b> <br><b>Ultima Genomics<\/b> Employment, Stock.<br><b>W. F. Hooper, <\/b> None..<br><b>R. Murray, <\/b> None..<br><b>D. Halmos, <\/b> None..<br><b>T. Langanay, <\/b> None..<br><b>G. Inghirami, <\/b> None..<br><b>S. Germer, <\/b> None..<br><b>M. Marton, <\/b> None..<br><b>A. Helland, <\/b> None..<br><b>R. Furatero, <\/b> None..<br><b>J. McClintock, <\/b> None..<br><b>L. Winterkorn, <\/b> None..<br><b>Z. Steinsnyder, <\/b> None..<br><b>Y. Wang, <\/b> None..<br><b>S. Rajagopalan, <\/b> None..<br><b>A. I. Alimohamed, <\/b> None..<br><b>M. S. Malbari, <\/b> None.&nbsp;<br><b>A. Saxena, <\/b> <br><b>AstraZeneca<\/b> Other, Research funding, Advisory board. <br><b>Blueprint Medicines<\/b> Other, Advisory board. <br><b>Jazz Pharmaceuticals<\/b> Other, Advisory board. <br><b>Genentech<\/b> Other, Consultant. <br><b>M. K. Callahan, <\/b> <br><b>BMS<\/b> Other, Consulting, Institutional support. <br><b>Merck<\/b> Other, Consulting. <br><b>InCyte<\/b> Other, Consulting. <br><b>Moderna<\/b> Other, Consulting. <br><b>ImmunoCore<\/b> Other, Consulting. <br><b>AstraZeneca<\/b> Other, Consulting.<br><b>D. T. Frederick, <\/b> None..<br><b>L. Spain, <\/b> None.&nbsp;<br><b>A. Jaimovich, <\/b> <br><b>Ultima Genomics<\/b> Employment, Stock. <br><b>D. Lipson, <\/b> <br><b>Ultima Genomics<\/b> Employment, Stock. <br><b>S. Turajlic, <\/b> <br><b>Roche<\/b> Other, Speaking fees. <br><b>AstraZeneca<\/b> Other, Speaking fees. <br><b>Novartis<\/b> Other, Speaking fees. <br><b>Ipsen<\/b> Other, Speaking fees.<br><b>M. C. Zody, <\/b> None..<br><b>N. K. Altorki, <\/b> None.&nbsp;<br><b>J. D. Wolchok, <\/b> <br><b>Apricity<\/b> Other, Consultant, equity. <br><b>CellCarta<\/b> Other, Consultant. <br><b>Ascentage Pharma<\/b> Other, Consultant. <br><b>AstraZeneca<\/b> Other, Consultant. <br><b>Astellas<\/b> Other, Consultant. <br><b>Bicara Therapeutics<\/b> Other, Consultant. <br><b>Boehringer Ingelheim<\/b> Other, Consultant. <br><b>Bristol Myers Squibb<\/b> Other, Consultant, Research support. <br><b>Daiichi Sankyo<\/b> Other, Consultant. <br><b>Dragonfly<\/b> Other, Consultant. <br><b>Georgiamune<\/b> Other, Consultant. <br><b>Imvaq<\/b> Other, Consultant, equity. <br><b>Larkspur<\/b> Other, Consultant. <br><b>Psioxus<\/b> Other, Consultant. <br><b>Recepta<\/b> Other, Consultant. <br><b>Tizona<\/b> Other, Consultant, equity. <br><b>Sephora<\/b> Other, Research support. <br><b>Arsenal IO<\/b> Other, Equity. <br><b>Beigene<\/b> Other, Equity. <br><b>Linneaus, Georgiamnue, Maverick, Trieza<\/b> Other, equity. <br><b>M. A. Postow, <\/b> <br><b>BMS<\/b> Other, Consulting, institutional support. <br><b>Merck<\/b> Other, Consulting, institutional support. <br><b>Novartis<\/b> Other, Consulting. <br><b>Eisai<\/b> Other, Consulting. <br><b>Pfizer<\/b> Other, Consulting. <br><b>Chugai<\/b> Other, Consulting. <br><b>Rgenix<\/b> Other, institutional support. <br><b>Infinity<\/b> Other, institutional support. <br><b>Novartis<\/b> Other, institutional support.<br><b>N. Robine, <\/b> None.&nbsp;<br><b>G. Boland, <\/b> <br><b>Olink Proteomics<\/b> Other, Sponsored research agreement. <br><b>Teiko Bio<\/b> Other, Sponsored research agreement. <br><b>InterVenn Biosciences<\/b> Other, Sponsored research agreement, consultant. <br><b>Palleon Pharmaceuticals<\/b> Other, Sponsored research agreement. <br><b>Iovance<\/b> Other, Advisory board. <br><b>Merck<\/b> Other, Advisory board, consultant. <br><b>Nektar Therapeutics<\/b> Other, Advisory board. <br><b>Novartis<\/b> Other, Advisory board. <br><b>Ankyra Therapeutics<\/b> Other, Advisory board, consultant, equity. <br><b>D. A. Landau, <\/b> <br><b>Illumina<\/b> Other, Research support, consulting. <br><b>Ultima Genomics<\/b> Other, Research support. <br><b>Cellgene<\/b> Other, Research support. <br><b>10X Genomics<\/b> Other, Research support. <br><b>Abbvie<\/b> Other, Research support. <br><b>C2i Genomics<\/b> Other, Co-founder, equity. <br><b>Pharmacyclics<\/b> Other, Consulting. <br><b>Mission Bio<\/b> Other, Consulting. <br><b>Pangea<\/b> Other, Consulting. <br><b>Alethiomics<\/b> Other, Consulting. <br><b>AstraZeneca<\/b> Other, Consulting.","End":"4\/18\/2023 2:52:00 PM","HasWebcast":null,"Highlights":[],"Id":"3278","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"4","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5709","PresenterBiography":null,"PresenterDisplayName":"Alexandre Cheng","PresenterKey":"1f671928-0c5b-46fe-aa8a-bb97e00c3d47","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5709. Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 2:37:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Whole genome error-corrected sequencing for sensitive circulating tumor DNA cancer monitoring","Topics":null,"cSlideId":""},{"Abstract":"Venetoclax (Ven) is a selective B-cell lymphoma 2 inhibitor being studied in t(11;14)+ relapsed\/refractory multiple myeloma (MM) Detection of t(11;14) in MM requires bone marrow (BM) aspiration and evaluation of CD138+ plasma cells by fluorescence in situ hybridization (FISH) Innovative techniques may provide less invasive detection of t(11;14) in liquid biopsies Here we present results of the SAGAsign&#174; integrated approach combining low-coverage whole-genome sequencing (WGS) to characterize t(11;14) breakpoints together with personalized digital polymerase chain reaction (dPCR) assays to efficiently detect and monitor the genomic rearrangements in circulating tumor DNA (ctDNA) Baseline BM aspirates were collected from 270 patients (pts) from Ven clinical trials (NCT02755597, NCT01794520, NCT03314181, NCT02899052) Previously generated WGS to an average coverage ~22&#215; was used Paired samples of peripheral blood mononuclear cell (PBMC) DNA and plasma circulating cell-free DNA (cfDNA) were analyzed by dPCR at timepoints after Ven-based treatment Of the 90 t(11;14)+ pts by FISH, 160 t(11;14) breakpoints were identified by WGS in 74 pts (concordance in Table) At the time of data cutoff, dPCR assays were designed and evaluated in 8 t(11;14)+ pts; 7\/8 (88%) and 6\/8 (75%) pts had detectable t(11;14) in cfDNA or PBMCs, respectively Higher levels of t(11;14) mutant allele frequency (MAF) were observed in cfDNA compared with PBMCs After Ven-based treatment, t(11;14) MAF in cfDNA became undetectable in pts with a complete response In conclusion, this approach has the capability to reconstruct t(11;14) breakpoints from WGS data that is highly concordant with FISH; translocations appear more readily detectable in cfDNA than PBMC samples from pts with MM SAGAsign assays detected and monitored t(11;14) in liquid biopsies thus highlighting its potential utility for identifying pts with t(11;14) for targeted therapies<br \/><table border=\"1\"  cellpadding=\"1\" class=\"DisplayTable\" id=\"{091B6767-76C9-4F14-91D7-574228B2F9B3}\"><caption>Concordance between WGS and FISH testing for t(11;14)<\/caption><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Samples, n<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">FISH+<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">FISH<\/span><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">&#8722;<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Total<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">WGS+<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">74<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">11<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">83<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">WGS<\/span><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-theme-font:minor-latin; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">&#8722;<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">16<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">169<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">187<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Total<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">90<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">180<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">270<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Concordance, %<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">n\/N<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">95% CI<\/span><\/b><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">t(11;14) positive&nbsp;<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">82.2<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">74\/90<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">72.7<\/span><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Arial&quot;,sans-serif; mso-fareast-font-family:Calibri;mso-fareast-theme-font:minor-latin;mso-ansi-language: EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">–<\/span><span style=\"font-size:11.0pt;line-height:115%;font-family:&quot;Calibri&quot;,sans-serif; mso-ascii-theme-font:minor-latin;mso-fareast-font-family:Calibri;mso-fareast-theme-font: minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;; mso-bidi-theme-font:minor-bidi;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">89.5<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">t(11;14) negative<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">93.9<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">169\/180<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">89.3–96.9<\/span><\/td><\/tr><tr><td rowspan=\"1\" colspan=\"1\"><b><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">Overall testing<\/span><\/b><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">90.0<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi; mso-ansi-language:EN-US;mso-fareast-language:EN-US;mso-bidi-language:AR-SA\">243\/270<\/span><\/td><td rowspan=\"1\" colspan=\"1\"><span style=\"font-size:11.0pt;line-height:115%; font-family:&quot;Calibri&quot;,sans-serif;mso-ascii-theme-font:minor-latin;mso-fareast-font-family: Calibri;mso-fareast-theme-font:minor-latin;mso-hansi-theme-font:minor-latin; mso-bidi-theme-font:minor-latin;mso-ansi-language:EN-US;mso-fareast-language: EN-US;mso-bidi-language:AR-SA\">85.8–93.3<\/span><\/td><\/tr><\/table>","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies: Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Multiple myeloma,Mutation detection,Predictive biomarkers,Liquid biopsies,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Xiaotong Li<sup>1<\/sup>, Lao H. Saal<sup>2<\/sup>, Christian Brueffer<sup>2<\/sup>, Yilun Chen<sup>2<\/sup>, Johanna Asklin<sup>2<\/sup>, Saman Alvi<sup>1<\/sup>, Srinivas Venkatram<sup>1<\/sup>, <b>Jeremy A. Ross<\/b><sup>1<\/sup><br><br\/><sup>1<\/sup>AbbVie Inc., North Chicago, IL,<sup>2<\/sup>SAGA Diagnostics, Lund, Sweden","CSlideId":"","ControlKey":"ddb53f8b-31a6-46b8-bd49-34e642a65724","ControlNumber":"4507","DisclosureBlock":"<b>&nbsp;X. Li, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock Option. <br><b>L. H. Saal, <\/b> <br><b>SAGA Diagnostics<\/b> Employment, Stock Option. <br><b>C. Brueffer, <\/b> <br><b>SAGA Diagnostics<\/b> Employment, Stock Option. <br><b>Y. Chen, <\/b> <br><b>SAGA Diagnostics<\/b> Employment, Stock Option. <br><b>J. Asklin, <\/b> <br><b>SAGA Diagnostics<\/b> Employment, Stock Option. <br><b>S. Alvi, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock Option. <br><b>S. Venkatram, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock Option. <br><b>J. A. Ross, <\/b> <br><b>AbbVie Inc.<\/b> Employment, Stock Option.","End":"4\/18\/2023 3:07:00 PM","HasWebcast":null,"Highlights":[],"Id":"3279","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"5","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5710","PresenterBiography":null,"PresenterDisplayName":"Jeremy Ross, MBA;PhD","PresenterKey":"510b8e2e-a1fc-4d74-8c81-2471d4f5497a","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5710. Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed\/refractory multiple myeloma treated with venetoclax-based regimens","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 2:52:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Detection and monitoring of t(11;14) in liquid biopsies from patients with relapsed\/refractory multiple myeloma treated with venetoclax-based regimens","Topics":null,"cSlideId":""},{"Abstract":"Background: Orphan non-coding RNAs (oncRNAs) are a novel category of small non-coding RNAs that are present in the tumor tissue and blood of people with cancer and largely absent in people without cancer. To examine the potential of using oncRNAs for early cancer detection via liquid biopsy, we assessed the oncRNA content of serum from people with and without non-small cell lung cancer (NSCLC) and developed a prediction model for NSCLC.<br \/>Methods: A total of 540 serum samples were obtained from Indivumed (Hamburg, Germany) and MT Group (Los Angeles, CA) and divided into cohort A for training (150 NSCLC cases, 219 controls; female: 30.7%\/36.1%; mean age: 67.9 &#177; 8.9\/62.4 &#177; 9.2; ever-smoker: 95.3%\/26.9%, respectively) and cohort B for internal validation (88 NSCLC cases, 83 controls; female: 40.9%\/54.2%; mean age: 62.7 &#177; 9.2\/54.1 &#177; 12.4; ever-smoker: 89.8%\/6.0%, respectively). We used RNA isolated from 0.5 mL of serum to generate and sequence libraries at an average depth of 18.5 &#177; 6.5 million 50-bp single-end reads using next-generation sequencing. Previously, we created a large catalog of NSCLC oncRNAs found in 999 NSCLC tumor tissues and largely absent in 679 normal samples from The Cancer Genome Atlas (TCGA) smRNA-seq database. This catalog was distilled by removing smRNA species found in the serum of an independent cohort of 31 non-cancer donors to yield a final NSCLC oncRNA catalog of 81,004 distinct oncRNA species. This distilled catalog was the reference for identifying NSCLC oncRNAs in the present study. Using oncRNA data we generated by sequencing samples from cohort A, we trained a logistic regression model for predicting NSCLC presence. The model was then validated in cohort B.<br \/>Results: From the 540 samples sequenced, we detected 64,379 oncRNAs from the distilled TCGA oncRNA catalog in at least one sample across both cohorts (A: 55,650, B: 47,539).Using 5-fold cross-validation, the AUC of the logistic regression model was 0.95 (95% CI: 0.93-0.97) for the training cohort, and was 0.98 (0.97-0.99) for the validation cohort. Sensitivities for detecting NSCLC at 95% specificity were 0.78 (0.69-0.86) for early stage (I\/II) cancer and 0.75 (0.60-0.87) for late stage (III\/IV) cancer in the training cohort, and 0.92 (0.83-0.98) and 1.0 (0.85-1.0), respectively, in the validation cohort.<br \/>Conclusion: These results demonstrate the potential for accurate, sensitive, and early detection of NSCLC through sequencing the oncRNA content of a routine blood draw. The performance of the model trained on one cohort and internally validated in a separate cohort supports the generalizability of this approach in detecting NSCLC.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies: Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Cancer,Liquid biopsies,RNA,Lung cancer: non-small cell,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Mehran Karimzadeh<sup><\/sup>, Jeffrey Wang<sup><\/sup>, Aiden Sababi<sup><\/sup>, Oluwadamilare  I.  Afolabi<sup><\/sup>, Dung Ngoc Lam<sup><\/sup>, Alice Huang<sup><\/sup>, Diana  R.  Corti<sup><\/sup>, Kristle  C.  Garcia<sup><\/sup>, Seda Kilinc<sup><\/sup>, Xuan Zhao<sup><\/sup>, Jieyang Wang<sup><\/sup>, Taylor  B.  Cavazos<sup><\/sup>, Patrick Arensdorf<sup><\/sup>, Kimberly  H.  Chau<sup><\/sup>, Helen Li<sup><\/sup>, Hani Goodarzi<sup><\/sup>, Lisa Fish<sup><\/sup>, Fereydoun Hormozdiari<sup><\/sup>, <b>Babak Alipanahi<\/b><sup><\/sup><br><br\/>Exai Bio Inc., Palo Alto, CA","CSlideId":"","ControlKey":"45ebf8ff-115e-4b35-a846-4725b76bcb98","ControlNumber":"3849","DisclosureBlock":"&nbsp;<b>M. Karimzadeh, <\/b> None..<br><b>J. Wang, <\/b> None..<br><b>A. Sababi, <\/b> None..<br><b>O. I. Afolabi, <\/b> None..<br><b>D. Lam, <\/b> None..<br><b>A. Huang, <\/b> None..<br><b>D. R. Corti, <\/b> None..<br><b>K. C. Garcia, <\/b> None..<br><b>S. Kilinc, <\/b> None..<br><b>X. Zhao, <\/b> None..<br><b>J. Wang, <\/b> None.&nbsp;<br><b>T. B. Cavazos, <\/b> <br><b>23andme<\/b> Other, intern. <br><b>P. Arensdorf, <\/b> <br><b>Intersect ENT<\/b> Stock. <br><b>Bluestar Genomics<\/b> Stock.<br><b>K. H. Chau, <\/b> None..<br><b>H. Li, <\/b> None..<br><b>H. Goodarzi, <\/b> None..<br><b>L. Fish, <\/b> None..<br><b>F. Hormozdiari, <\/b> None.&nbsp;<br><b>B. Alipanahi, <\/b> <br><b>23andMe<\/b> Stock. <br><b>Deep Genomics<\/b> Stock. <br><b>Guardant Health<\/b> Stock. <br><b>AstraZeneca<\/b> Stock. <br><b>Ionis<\/b> Stock.","End":"4\/18\/2023 3:22:00 PM","HasWebcast":null,"Highlights":[],"Id":"3280","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"6","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5711","PresenterBiography":null,"PresenterDisplayName":"Babak Alipanahi, PhD","PresenterKey":"9d59583a-3b47-488c-89be-ab4cda7eaabd","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5711. Blood-based early detection of non-small cell lung cancer using orphan noncoding RNAs","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 3:07:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Blood-based early detection of non-small cell lung cancer using orphan noncoding RNAs","Topics":null,"cSlideId":""},{"Abstract":"Background: TIGIT is a co-inhibitory receptor and immune checkpoint associated with T cell and natural killer (NK) cell dysfunction in cancer. Tiragolumab is an anti-TIGIT antibody with an active IgG1\/kappa Fc. In a randomized double-blind phase 2 clinical trial in non-small cell lung cancer (NSCLC), tiragolumab + atezolizumab (anti-PD-L1) combination treatment demonstrated significant improvement relative to atezolizumab alone. However, the mechanisms underlying the efficacy of this combination are not well understood.<br \/>Methods: In CITYSCAPE (phase 2, NCT03563716), chemotherapy-na&#239;ve patients with locally advanced\/metastatic NSCLC received either placebo + 1200 mg atezolizumab or 600 mg tiragolumab + 1200 mg atezolizumab q3w IV. We collected tumor pretreatment samples and serum samples (baseline and on-treatment) from patients enrolled in the trial, which were subject to bulk RNA-seq and proteomics, respectively. In the mouse tumor model, BALB\/c mice were implanted with syngeneic CT26 tumors. After tumor establishment, mice were randomized by tumor volume and then treated with control IgG2a, anti-PD-L1, anti-TIGIT IgG2a-LALAPG (Fc-inactive) &#177; anti-PD-L1, anti-TIGIT IgG2b &#177; anti-PD-L1, or anti-TIGIT IgG2a &#177; anti-PD-L1. Three days after treatment, CD45+ immune cells were collected from the peripheral blood and tumor from selected treatment groups and underwent single cell RNA sequencing or flow cytometry profiling. Tumor growth was also monitored to determine efficacy.<br \/>Results: Here, we show that tiragolumab functions as both a conventional checkpoint inhibitor and, via Fc gamma receptor engagement, as a modulator of immunosuppressive myeloid cells and T regulatory (Treg) cells. Gene expression analysis of patient tumor samples revealed high levels of these cell subsets, were instead associated with treatment benefit in the tiragolumab + atezolizumab arm but not atezolizumab arm. Analysis of patient serum proteins suggested an association of myeloid cell activation with clinical benefit mediated by the combination therapy. In mouse tumor models, treatment with anti-PD-L1 + anti-TIGIT IgG2a (but not anti-TIGIT IgG2b or Fc-silent anti-TIGIT) led to effective tumor control in mice, suggesting a pivotal role for activating Fc receptors. Phenotypic profiling by single cell RNAseq and flow cytometry revealed that Fc-active anti-TIGIT remodels the tumor microenvironment, most prominently by inducing antigen presentation machinery in myeloid cells, counteracting of anti-PDL1-enforced CD8+ T cell exhaustion, and reducing Treg suppressive capacity.<br \/>Conclusions: These findings reveal that FcR engagement is one of several distinct mechanisms by which tiragolumab unleashes antitumor immune responses, and inform further clinical development of anti-TIGIT therapies.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-09 Other,,"},{"Key":"Keywords","Value":"Checkpoint Inhibitors,TIGIT,PD-L1,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Namrata  S.  Patil<\/b><sup>1<\/sup>, Shyam Srivats<sup>1<\/sup>, Yoonha Choi<sup>1<\/sup>, Xiangnan Guan<sup>1<\/sup>, Barzin Nabet<sup>1<\/sup>, Lisa McGinnis<sup>1<\/sup>, Eugene Chiang<sup>1<\/sup>, Alexis Dunkle<sup>1<\/sup>, Bill O’Gorman<sup>1<\/sup>, Patrick  S.  Chang<sup>1<\/sup>, Ruozhen Hu<sup>1<\/sup>, John Silva<sup>1<\/sup>, Joy Han<sup>1<\/sup>, Amelia Au-Yeung<sup>1<\/sup>, Chikara Takahashi<sup>1<\/sup>, Nandini Molden<sup>1<\/sup>, Pallavi Daggumati<sup>1<\/sup>, Wendy Connolly<sup>1<\/sup>, Melissa Johnson<sup>2<\/sup>, Delvys Rodriguez Abreu<sup>3<\/sup>, Byoung Chul Cho<sup>4<\/sup>, Antoine Italiano<sup>5<\/sup>, Ignacio Gil-Bazo<sup>6<\/sup>, Enriqueta Felip<sup>7<\/sup>, Ira Mellman<sup>1<\/sup>, Raymond Meng<sup>1<\/sup>, Sanjeev Mariathasan<sup>1<\/sup>, Robert Johnston<sup>1<\/sup>, David  S.  Shames<sup>1<\/sup><br><br\/><sup>1<\/sup>Genentech Inc., South San Francisco, CA,<sup>2<\/sup>Sarah Cannon Research Institute\/Tennessee Oncology, Nashville, TN,<sup>3<\/sup>Hospital Universitario Insular de Gran Canaria, Las Palmas, Spain,<sup>4<\/sup>Yonsei Cancer Centre, Yonsei University College of Medicine, Seoul, CA,<sup>5<\/sup>Institut Bergonie CLCC Bordeaux, Bordeaux, France,<sup>6<\/sup>Clínica Universidad de Navarra, CIMA Universidad de Navarra Pamplona, Pamplona, Spain,<sup>7<\/sup>Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain","CSlideId":"","ControlKey":"851045ff-bdcd-4b99-85fe-84e9f94db60d","ControlNumber":"2443","DisclosureBlock":"<b>&nbsp;N. S. Patil, <\/b> <br><b>Genentech, Inc.<\/b> Employment.<br><b>S. Srivats, <\/b> None.&nbsp;<br><b>Y. Choi, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>X. Guan, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>B. Nabet, <\/b> <br><b>Genentech, Inc.<\/b> Employment, Stock. <br><b>L. McGinnis, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>E. Chiang, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>A. Dunkle, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>B. O’Gorman, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>P. S. Chang, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>R. Hu, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>J. Silva, <\/b> <br><b>Genentech, Inc.; F. Hoffmann-La Roche<\/b> Employment. <br><b>J. Han, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>A. Au-Yeung, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>C. Takahashi, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>N. Molden, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>P. Daggumati, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>W. Connolly, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>M. Johnson, <\/b> <br><b>AbbVie, Acerta, Adaptimmune, Amgen,\u0009Apexigen, Arcus Biosciences, Array BioPharma, Artios Pharma, AstraZeneca, Atreca, BeiGene, BerGenBio, BioAtla, Black Diamond, Boehringer Ingelheim, Calithera Bio<\/b> Other, Research funding - all payments made to institution. <br><b>Corvus Pharmaceuticals, Curis, CytomX, Daiichi Sankyo, Dracen Pharmaceuticals, Dynavax, Lilly, Elicio Therapeutics, EMD Serono, EQRx, Erasca, Exelixis, Fate Therapeutics<\/b> Other, Research funding - all payments made to institution. <br><b>Genentech\/Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon, Helsinn Healthcare SA, Hengrui Therapeutics, Hutchison MediPharma, IDEAYA Biosciences<\/b> Other, Research funding - all payments made to institution. <br><b>IGM Biosciences, Immunocore, Impact, Incyte, Janssen, Kadmon Pharmaceuticals, Kartos Therapeutics, Loxo Oncology, Lycera, Memorial Sloan-Kettering<\/b> Other, Research funding - all payments made to institution. <br><b>Merck, Merus, Mirati Therapeutics, NeoImmune Tech, Neovia Oncology, Novartis, Numab Therapeutics, Nuvalent, OncoMed Pharmaceuticals, Palleon Pharmaceuticals, Pfizer, PMV Pharmaceuticals<\/b> Other, Research funding - all payments made to institution. <br><b>Rain Therapeutics, RasCal Therapeutics, Regeneron Pharmaceuticals, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi, Seven and Eight Biopharmaceuticals\/Birdie<\/b> Other, Research funding - all payments made to institution. <br><b>Shattuck Labs, Silicon Therapeutics, Stem CentRx,\u0009Syndax Pharmaceuticals  •\u0009Takeda Pharmaceuticals  •\u0009Tarveda  •\u0009TCR2 Therapeutics •\u0009Tempest Therapeutics, Tizona Therapeutics, TMUNITY Therapeutics<\/b> Other, Research funding - all payments made to institution. <br><b>Turning Point Therapeutics, University of Michigan, Vyriad, Y-mAbs Therapeutics<\/b> Other, Research funding - all payments made to institution. <br><b>AbbVie, Amgen, Astellas, AstraZeneca, Axelia Oncology, Black Diamond, Calithera Biosciences, Checkpoint Therapeutics, CytomX Therapeutics, Daiichi Sankyo, EcoR1, Editas Medicine, Eisai, EMD Serono<\/b> Consulting\/advisory role - all payments made to institution. <br><b>G1 Therapeutics, Genentech \/ Roche, Genmab, Genocea Biosciences, GlaxoSmithKline, Gritstone Oncology, Ideaya Biosciences, iTeos, Janssen, Lilly, Merck, Mirati Therapeutics, Molecular Axiom<\/b> Other, Consulting\/advisory role - all payments made to institution. <br><b>Novartis, Oncorus, Regeneron Pharmaceuticals, Ribon Therapeutics, Sanofi-Aventis, Turning Point Therapeutics, VBL Therapeutics<\/b> Other, Consulting\/advisory role - all payments made to institution.<br><b>D. Rodriguez Abreu, <\/b> None.&nbsp;<br><b>B. Cho, <\/b> <br><b>Champions Oncology<\/b> Other, Royalties. <br><b>MOGAM Institute, LG Chem, Oscotec, Interpark Bio Convergence Corp, GIInnovation, GI-Cell, Abion, Abbvie, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, Champions Onoclogy<\/b> Grant\/Contract. <br><b>CJ bioscience, CJ Blossom Park, Cyrus, Dizal Pharma, Genexine, Janssen, Lilly, MSD, Novartis, Nuvalent, Oncternal, Ono, Regeneron, Dong-A ST, Bridgebio therapeutics, Yuhan, ImmuneOncia, Illumina<\/b> Grant\/Contract. <br><b>Kanaph therapeutics, Therapex, JINTSbio, Hanmi<\/b> Grant\/Contract. <br><b>Abion, BeiGene, Novartis, AstraZeneca, Boehringer-Ingelheim, Roche, BMS, CJ, CureLogen, Cyrus therapeutics, Ono, Onegene Biotechnology, Yuhan, Pfizer, Eli Lilly, GI-Cell, Guardant, HK Inno-N<\/b> Other, Consultant. <br><b>Imnewrun Biosciences Inc.,  Janssen, Takeda, MSD, Janssen, Medpacto, Blueprint medicines, RandBio, Hanmi<\/b> Other, Consultant. <br><b>Yonsei University Health System<\/b> Employment. <br><b>KANAPH Therapeutic Inc, Bridgebio therapeutics, Cyrus therapeutics, Guardant Health, Oscotec Inc<\/b> Other, Advisory board. <br><b>ASCO, AstraZeneca, Guardant, Roche, ESMO, IASLC, Korean Cancer Association, Korean Society of Medical Onoclogy, Korean Society of Thyroid-Head and Neck Surgery, Korean Cancer Study Group, Novartis<\/b> Other, Invited speaker. <br><b>MSD, The Chinese Thoracic Oncology Society, Pfizer<\/b> Other, Invited speaker. <br><b>TheraCanVac Inc, Gencurix Inc, Bridgebio therapeutics, KANAPH Therapeutic Inc, Cyrus therapeutics, Interpark Bio Convergence Corp., J INTS BIO<\/b> Stock. <br><b>DAAN Biotherapeutics<\/b> Other, Founder. <br><b>Interpark Bio Convergence Corp.,  J INTS BIO<\/b> Other, Member of the board of directors.<br><b>A. Italiano, <\/b> None.&nbsp;<br><b>I. Gil-Bazo, <\/b> <br><b>Fundacion Instituto Valenciano de Oncologia (FIVO)<\/b> Employment. <br><b>MSD, Roche<\/b> Travel. <br><b>MSD, Boehringer, Lilly, Sanofi<\/b> Other, Consultant. <br><b>E. Felip, <\/b> <br><b>MERCK HEALTHCARE KGAa<\/b> Grant\/Contract, RESEARCH FUNDING TO INSTITUTION. <br><b>FUNDACIÓN MERCK SALUD<\/b> Grant\/Contract, RESEARCH FUNDING TO INSTITUTION. <br><b>AMGEN, ASTRAZENECA, BAYER, BRISTOL-MYERS SQUIBB, DAICHI SANKYO, ELI LILLY, F. HOFFMANN-LA ROCHE, GSK, JANSSEN, MERCK SERONO, MERCK SHARP & DOHME, NOVARTIS, PEPTOMYC, PFIZER, SANOFI, TAKEDA<\/b> Other, Consulting fees\u000d\u000a. <br><b>AMGEN, ASTRA ZENECA, BRISTOL MYERS SQUIBB, ELI LILLY, F. HOFFMANN-LA ROCHE, JANSEN, MEDICAL TRENDS, MEDSCAPE, MERCK SERONO, MERCK SHARP & DOHME, PEERVOICE, PFIZER, SANOFI, TAKEDA, TOUCH ONCOLOGY.<\/b> Other, Honoraria. <br><b>GRÍFOLS<\/b> Other, DR. FELIP IS AN INDEPENDENT MEMBER OF THE BOARD.&nbsp;<br><b>I. Mellman, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>R. Meng, <\/b> <br><b>Genentech, Inc.<\/b> Employment, Stock, Patent. <br><b>S. Mariathasan, <\/b> <br><b>Genentech, Inc.<\/b> Employment. <br><b>R. Johnston, <\/b> <br><b>Genentech, Inc.<\/b> Employment, Stock, Stock Option. <br><b>D. S. Shames, <\/b> <br><b>Genentech, Inc.<\/b> Employment.","End":"4\/18\/2023 3:37:00 PM","HasWebcast":null,"Highlights":[],"Id":"3281","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"7","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5712","PresenterBiography":null,"PresenterDisplayName":"Namrata Patil, PhD","PresenterKey":"17cb6d29-2434-465b-8225-7cb6a0794297","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5712. Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 3:22:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade","Topics":null,"cSlideId":""},{"Abstract":"Introduction: Links between cancer and microbes date back four millennia (Sepich-Poore et al. 2021. <i>Science<\/i>). Recently, we found that microbial DNA is detectable in tumor tissues and patient blood from many human cancer types (Poore et al. 2020. <i>Nature<\/i>). These intratumoral and bloodborne microbiomes were distinct between cancer types, between normal and malignant tissues, and present in cell-free plasma samples. However, the practical utility of cell-free microbial DNA (cf-mbDNA) as a bona fide liquid biopsy diagnostic, including its applicability in early-stage disease in treatment-na&#239;ve individuals, distinguishing histological subtypes, and discriminating against non-cancer-but-diseased patients remains unknown. Thus, we constructed an age and sex-matched cohort of &#62;1000 individuals with lung cancer, lung disease, and no disease (healthy) to evaluate the utility of a cf-mbDNA-driven liquid biopsy diagnostic.<br \/>Methods: Shallow shotgun metagenomic sequencing with gold-standard positive and negative controls was performed using 400 &#181;L of patient plasma. Direct genome alignments separated human and microbial reads, and generated genome-wide binned and species-level abundances, respectively. Novel taxonomic diversity was captured by additionally performing <i>de novo<\/i> co-assemblies in tandem with tumor and blood samples from The Cancer Genome Atlas (TCGA). Multi-modal, stacked machine learning classifiers then evaluated the diagnostic performance of microbial-only and multi-species (microbial + human) information.<br \/>Results: Cf-mbDNA provides strong diagnostic performance in treatment-na&#239;ve, cancer-bearing individuals versus age and sex-matched healthy controls, as early as stage I disease (AUROCs&#8805;0.90). Furthermore, cf-mbDNA outperforms histological classification compared to human genomic information. Multi-species models paired with routinely-available clinicodemographic information provided robust discrimination of lung cancer versus lung diseases (AUROC&#8805;0.80). Importantly, the addition of cell-free microbial information produced an integrated model surpassing the diagnostic performance of PET-CT and clinical risk models for lung nodule malignancy determination in a blinded validation cohort of Stage I lung cancer and non-cancer lung disease samples.<br \/>Conclusion: Cf-mbDNA features comprise a novel class of biomarkers that are combinable with host analytes, and show promise for real-world, early-stage, lung cancer diagnosis.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-04 Liquid biopsies: Circulating nucleic acids,,"},{"Key":"Keywords","Value":"Cancer diagnostics,Cancer microbiome,Liquid biopsies,Metagenome assembly,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"Serena Fraraccio<sup>1<\/sup>, Stephen Wandro<sup>1<\/sup>, Akanksha Singh-Taylor<sup>1<\/sup>, Sandrine Miller-Montgomery<sup>1<\/sup>, Eddie Adams<sup>1<\/sup>, Rob Knight<sup>2<\/sup>, Leopoldo  N.  Segal<sup>3<\/sup>, Harvey  I.  Pass<sup>4<\/sup>, <b>Gregory  D.  Sepich-Poore<\/b><sup>1<\/sup><br><br\/><sup>1<\/sup>Research & Development, Micronoma, Inc., San Diego, CA,<sup>2<\/sup>Department of Bioengineering, Department of Pediatrics, Department of Computer Science and Eng., University of California San Diego, San Diego, CA,<sup>3<\/sup>Division of Pulmonary and Critical Care Medicine, New York University School of Medicine, New York, NY,<sup>4<\/sup>Department of Cardiothoracic Surgery, New York University School of Medicine, New York, NY","CSlideId":"","ControlKey":"b83e71fd-a590-4788-bba4-9a63fae03f2c","ControlNumber":"3710","DisclosureBlock":"<b>&nbsp;S. Fraraccio, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock Option, Patent. <br><b>S. Wandro, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock Option, Patent. <br><b>A. Singh-Taylor, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock Option, Patent. <br><b>S. Miller-Montgomery, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock, Stock Option, Other Business Ownership, Patent. <br><b>E. Adams, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock Option, Patent. <br><b>R. Knight, <\/b> <br><b>Micronoma, Inc.<\/b> Stock, Stock Option, Other Business Ownership, Patent. <br><b>GenCirq<\/b> Stock, Other Business Ownership.<br><b>L. N. Segal, <\/b> None..<br><b>H. I. Pass, <\/b> None.&nbsp;<br><b>G. D. Sepich-Poore, <\/b> <br><b>Micronoma, Inc.<\/b> Employment, Stock, Stock Option, Other Business Ownership, Patent.","End":"4\/18\/2023 3:52:00 PM","HasWebcast":null,"Highlights":[],"Id":"3282","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"8","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5713","PresenterBiography":null,"PresenterDisplayName":"Gregory Sepich-Poore, PhD","PresenterKey":"6de34a7c-5e63-4ed7-b74e-774cadf514d1","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5713. Assessing the real-world utility of cell-free microbial DNA in diagnosing early-stage lung cancer","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 3:37:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Assessing the real-world utility of cell-free microbial DNA in diagnosing early-stage lung cancer","Topics":null,"cSlideId":""},{"Abstract":"BACKGROUND: Cell-free circulating tumor DNA (ctDNA) assays have been adopted to monitor therapeutic response in both early- and late-stage cancer. However, tests currently available require deep-targeted sequencing to detect cancer-specific mutations at low mutant allele frequency (MAF) levels in the circulation. Recently, we developed a tumor-agnostic approach called DELFI Tumor Fraction (DELFI-TF), a Bayesian probabilistic model designed to predict plasma tumor fractions based on genome-wide fragmentation-related features.<br \/>METHODS: Overall, 692 longitudinal plasma samples collected from 153 patients with initially unresectable colorectal cancer (CRC) liver-only metastases participating in the phase III study CAIRO5 (NCT02162563) were split across a training (RAS\/BRAF mutant) and a validation cohort (RAS\/BRAF wildtype). For all cell-free DNA (cfDNA) samples of patients within the training cohort (n=312), the tumor burden was quantified as the MAF of the tumor-tissue-proven RAS\/BRAF variant measured by digital droplet PCR (ddPCR). Using cfDNA fragment-sequencing statistics from low-coverage WGS data, a Bayesian regression model was trained against the MAF of the tumor-specific driver RAS\/BRAF variant in all longitudinal timepoints in the training cohort. Changes in DELFI-TF scores during first-line FOLFOX\/FOLFIRI and bevacizumab therapy were assessed to predict disease response. A tissue-informed approach was applied to detect minimal residual disease in the subgroup of patients treated with curative intent (complete resection of the primary tumor and liver metastases).<br \/>RESULTS: In the training cohort, DELFI-TF scores strongly correlated with RAS\/BRAF MAF measured by ddPCR (r=0.85, p&#60;0.001). DELFI-TF captured plasma tumor fractions associated with copy number changes when ddPCR failed to detect RAS\/BRAF mutations. Before treatment initiation, DELFI-TF correlated with the sum of the largest diameters on CT scans according to RECIST1.1 (r=0.49, p&#60;0.001). Patients with negative and positive changes in DELFI-TF more often exhibited response and progressive disease based on consecutive RECIST assessments, respectively. Median progression-free survival was 9.9 and 12.8 months for patients with DELFI-TF low versus DELFI-TF high, respectively (p=0.007). Overall survival was 28.8 and 58.9 months for patients with DELFI-TF low versus DELFI-TF high, respectively (p=0.001). In patients treated with curative intent, tissue-informed focal and arm-level copy number changes were detected 4-12 weeks after metastasectomy. Most patients presenting molecular relapse were later diagnosed with clinical recurrence by conventional CT imaging.<br \/>CONCLUSIONS: DELFI-TF demonstrates the ability to use cfDNA fragmentomes to estimate cfDNA tumor burden with a performance comparable to standard approaches for treatment response monitoring and clinical outcome prediction.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Abstract Submission","AdditionalFields":[{"Key":"Topics","Value":"++CL01-05 Liquid biopsies: Circulating tumor cells,,"},{"Key":"Keywords","Value":"Cell-free DNA,Monitoring therapeutic response in cancer,Colorectal cancer,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<b>Bahar Alipanahi<\/b><sup>1<\/sup>, Iris van 't Erve<sup>2<\/sup>, Keith Lumbard<sup>1<\/sup>, Laurel K. Millberg<sup>1<\/sup>, Zach Skidmore<sup>1<\/sup>, Lorenzo Rinaldi<sup>1<\/sup>, Jacob Carey<sup>1<\/sup>, Jennifer Tom<sup>1<\/sup>, Cornelis J. A. Punt<sup>3<\/sup>, Nicholas C. Dracopoli<sup>1<\/sup>, Gerrit A. Meijer<sup>2<\/sup>, Robert B. Scharpf<sup>1<\/sup>, Victor E. Velculescu<sup>4<\/sup>, Remond Fijneman<sup>2<\/sup>, Alessandro Leal<sup>1<\/sup><br><br\/><sup>1<\/sup>Delfi Diagnostics, Baltimore, MD,<sup>2<\/sup>Netherlands Cancer Institute, Amsterdam, Netherlands,<sup>3<\/sup>University Medical Center Utrecht, Utrecht, Netherlands,<sup>4<\/sup>The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD","CSlideId":"","ControlKey":"03e8c555-6cba-45af-bf9b-d6bf05eb398a","ControlNumber":"5115","DisclosureBlock":"<b>&nbsp;B. Alipanahi, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other Intellectual Property.<br><b>I. van 't Erve, <\/b> None.&nbsp;<br><b>K. Lumbard, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other Intellectual Property. <br><b>L. K. Millberg, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other Intellectual Property. <br><b>Z. Skidmore, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock. <br><b>L. Rinaldi, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other Intellectual Property. <br><b>J. Carey, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other Intellectual Property. <br><b>J. Tom, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock.<br><b>C. J. A. Punt, <\/b> None.&nbsp;<br><b>N. C. Dracopoli, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Other, Co-Founder. <br><b>G. A. Meijer, <\/b> <br><b>KWF\/SU2C<\/b> Grant\/Contract. <br><b>MLDS<\/b> Grant\/Contract. <br><b>Exact Sciences<\/b> Grant\/Contract, Other, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>Health~Holland<\/b> Grant\/Contract. <br><b>ZonMW<\/b> Grant\/Contract. <br><b>HMF<\/b> Grant\/Contract. <br><b>Sysmex<\/b> Grant\/Contract, Other, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>CZ health insurance<\/b> Grant\/Contract. <br><b>PGDX<\/b> Grant\/Contract, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>Health-RI<\/b> Other, board member, CSO. <br><b>IKNL<\/b> Other, member supervisory board. <br><b>BBMRI-NL<\/b> Other, co-national node director. <br><b>EATRIS-NL<\/b> Other, national node director. <br><b>CRCbioscreen BV<\/b> Stock, Other, co-founder and board member(CSO). <br><b>Sentinel Ch. SpA<\/b> Other, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>Hartwig Medical Foundation<\/b> Other, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>Delfi Diagnostics<\/b> Other, Research collaboration; the company provided materials, equipment, or (sample) analyses. <br><b>AMGEN<\/b> Other, real-world data group (unpaid). <br><b>R. B. Scharpf, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Patent, Other Intellectual Property, Other, Co-Founder. <br><b>V. E. Velculescu, <\/b> <br><b>Delfi Diagnostics<\/b> Fiduciary Officer, Stock, Grant\/Contract, Patent, Other Intellectual Property, Other, Co-Founder. <br><b>R. Fijneman, <\/b> <br><b>Dutch Cancer Society<\/b> Grant\/Contract. <br><b>Health Holland<\/b> Grant\/Contract. <br><b>A. Leal, <\/b> <br><b>Delfi Diagnostics<\/b> Employment, Stock, Patent, Other, Co-Founder.","End":"4\/18\/2023 4:07:00 PM","HasWebcast":null,"Highlights":[],"Id":"3283","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"9","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"5714","PresenterBiography":"","PresenterDisplayName":"Bahar Alipanahi","PresenterKey":"6ede17e4-bc08-45f3-8287-8c582dcb4478","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"5714. Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 3:52:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Cell-free DNA fragmentation profiling for monitoring therapeutic response in metastatic colorectal cancer","Topics":null,"cSlideId":""},{"Abstract":"There is no abstract associated with this presentation.","Actions":[{"Icon":null,"Label":"View Abstract","SubType":null,"Type":"ViewAbstract","Url":null},{"Icon":null,"Label":"View Video","SubType":null,"Type":"ViewPlayer","Url":null},{"Icon":null,"Label":"Rating","SubType":null,"Type":"Rating","Url":null}],"Activity":"Invited Speaker","AdditionalFields":[{"Key":"Topics","Value":",,"},{"Key":"Keywords","Value":",,,,"},{"Key":"ePosterClassification","Value":""},{"Key":"ePosterNote","Value":""},{"Key":"VideoType","Value":""},{"Key":"cSlidePresentationId","Value":""},{"Key":"ePosterLink","Value":""},{"Key":"WebcastProgramPlannerLink","Value":""}],"AdditionalFiles":[],"AllowAttendeeRating":"False","AttendeeRatingAvg":"0","AttendeeRatingCount":"0","AuthorBlock":"<presenter><u><i>Muhammed Murtaza<\/i><\/u><\/presenter>. University of Wisconsin Carbone Cancer Center, Madison, WI","CSlideId":"","ControlKey":"1d67891c-9d03-44aa-8600-c1e68e38c783","ControlNumber":"11060","DisclosureBlock":"<b>&nbsp;M. Murtaza, <\/b> <br><b>Castle Biosciences, Inc<\/b> I, I, I, I, I. <br><b>Exact Sciences<\/b> P, P, P, P, P. <br><b>PetDx<\/b> I, I, I, I, I. <br><b>Translational Genomics Research Institute<\/b> I, I, I, I, I.","End":"4\/18\/2023 4:15:00 PM","HasWebcast":null,"Highlights":[],"Id":"10838","IsPresentation":"True","IsSessionOrganizer":"False","Keywords":null,"MediaSource":"None","OtherContent":null,"PlayerUrl":null,"PlayerUrlReason":null,"PositionInSession":"10","PosterboardNumber":"","PresentationFiles":null,"PresentationMediaItemId":null,"PresentationMediaItemKey":null,"PresentationNumber":"","PresenterBiography":null,"PresenterDisplayName":"Muhammed Murtaza, MBBS;PhD","PresenterKey":"dc26c9ab-5fe1-43a5-aaee-97990968c93d","PresenterPhoto":null,"SearchResultActions":null,"SearchResultBody":"Closing remarks","SearchResultFooter":"","SearchResultHeader":"Apr 18 2023  2:30PM","SessionId":"530","SessionOnDemand":"False","SessionTitle":"Increasing the Clinical Utility of Cell-Free DNA Testing","ShowChatLink":"false","Start":"4\/18\/2023 4:07:00 PM","Status":"Presenting","Tags":null,"ThumbnailUrl":null,"Title":"Closing remarks","Topics":null,"cSlideId":""}]